1
|
Harden SV, Routsis DS, Geater AR, Thomas SJ, Coles C, Taylor PJ, Marcus RE, Williams MV. Total body irradiation using a modified standing technique: a single institution 7 year experience. Br J Radiol 2001; 74:1041-7. [PMID: 11709470 DOI: 10.1259/bjr.74.887.741041] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
We describe a simple standing technique for delivering total body irradiation (TBI) using large horizontal fields, made possible by the off-centre installation of a non-dedicated treatment unit in a pre-existing bunker. Patients are treated using anterior and posterior fields with customized lung compensators. This technique enables the dose to the lung to be accurately calculated and modified to avoid overdose and to minimize the risk of pneumonitis. From February 1991 to December 1997, 94 patients with a variety of haematological malignancies were given fractionated TBI using this technique prior to allogenic or autologous bone marrow transplantation. Patients received a total dose of 14.4 Gy given in eight fractions over 4 days, with at least 6 h between fractions. The prescribed dose to the lungs was reduced to 12 Gy in eight fractions. The technique was well tolerated, took less than 10 min to set up and did not disrupt the daily routine use of the machine. Doses to all measured points on the trunk and head were within +/-6% of the prescribed dose. Doses to the lungs were within +/-5% of the prescribed dose. There were no early respiratory deaths in the 37 autologous transplant patients. There were 10 (17%) respiratory deaths in the 57 allogeneic transplant patients, 3 of confirmed infectious aetiology.
Collapse
Affiliation(s)
- S V Harden
- Department of Clinical Oncology, Box 193, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP, Mackinnon S, Apperley J, Barrett AJ, Hows JM. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol 1992; 81:383-90. [PMID: 1390211 DOI: 10.1111/j.1365-2141.1992.tb08244.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We have analysed the results of treating 140 consecutive patients with chronic myeloid leukaemia (CML) in chronic phase by bone marrow transplantation (BMT) using marrow from HLA-identical siblings performed between February 1981 and July 1991. Three different regimens were used sequentially to prevent graft-versus-host disease (GVHD): cyclosporin A (CsA) alone (n = 39), T-cell depletion of donor marrow (n = 51) and CsA with methotrexate (MTX) (n = 50). Eighty-four patients (61%) survive at a median of 49 months from BMT (range 3-120). The actuarial overall and leukaemia-free survivals at 5 years were 52% and 41% respectively. The actuarial probabilities of leukaemia-free survival and haematological relapse at 2 years for the CsA only group were 65% and 4%, for the T-cell depletion group 40% and 41% and for the CsA/MTX group 68% and 6% respectively. For the T-cell depletion group the probability of leukaemia-free survival was significantly lower (P less than 0.001) and the probability of relapse significantly higher (P less than 0.001) than for other methods of GVHD prophylaxis; differences between the other two groups were not significant. Previous reports that T-cell depletion with Campath-1M results in a high rate of relapse are confirmed. Patients in the CsA/MTX group have been monitored with cytogenetic and polymerase chain reaction studies for residual BCR/ABL transcripts. We conclude that the combination of CsA/MTX is currently the best available approach to prevention of GVHD after BMT for CML and in our hands it is not associated with a major risk of relapse.
Collapse
MESH Headings
- Adolescent
- Adult
- Bone Marrow Transplantation/immunology
- Child
- Cyclosporine/therapeutic use
- DNA, Neoplasm/genetics
- Drug Therapy, Combination
- Female
- Fusion Proteins, bcr-abl/genetics
- Graft vs Host Disease/immunology
- Graft vs Host Disease/prevention & control
- HLA Antigens/immunology
- Histocompatibility/immunology
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Male
- Methotrexate/therapeutic use
- Middle Aged
- Polymerase Chain Reaction
- Prognosis
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- Recurrence
- Transcription, Genetic/genetics
Collapse
Affiliation(s)
- D I Marks
- Department of Haematology, Royal Postgraduate Medical School, Hammersmith Hospital, London
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Ozsahin M, Pène F, Touboul E, Gindrey-Vie B, Dominique C, Lefkopoulos D, Krzisch C, Balosso J, Vitu L, Schwartz LH. Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients. Cancer 1992; 69:2853-65. [PMID: 1571917 DOI: 10.1002/1097-0142(19920601)69:11<2853::aid-cncr2820691135>3.0.co;2-2] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
One hundred fifty-seven patients referred to the Department of Radiation Oncology of the Hôpital Tenon, Paris, France, between December 10, 1986 and December 31, 1989 for total-body irradiation (TBI) were treated according to the following two techniques: (1) either in one fraction (1000 cGy administered to the midplane at L4 and 800 cGy to the lungs) or (2) in six fractions (1200 cGy on 3 consecutive days to the midplane at L4 and 900 cGy to the lungs). The patients were randomized according to two instantaneous dose rates, called LOW and HIGH, in single-dose (6 versus 15 cGy/min) and hexafractionated (3 versus 6 cGy/min) TBI groups. There were 77 patients in the LOW group and 80 in the HIGH group, with 57 patients receiving single-dose TBI (28 LOW and 29 HIGH) and 100 patients receiving fractionated-dose TBI (49 LOW and 51 HIGH). In March 1991, the 4-year relapse-free and overall survival rates were 58.4% and 52.1%, respectively. The 4-year relapse-free survival and survival rates were 54.9% and 50.7% in the LOW group; 61.9% and 53.5% in the HIGH group (P = 0.69 and 0.82, respectively); 60.3% and 50.4% in the single-dose group; and 57.9% and 53.3% in the fractionated group (P = 0.65 and 0.78, respectively). There was no difference in the incidence of graft versus host disease, interstitial pneumonitis, or venoocclusive disease either between the LOW and the HIGH groups or between the single-dose and fractionated-dose TBI groups. The 4-year estimated cataract incidence was significantly higher in the single-dose HIGH instantaneous dose rate group than in the LOW instantaneous dose rate TBI group (P = 0.049). Multivariate analyses showed that instantaneous dose rate and fractionation do not influence the relapse-free and overall survival rates or the incidence of interstitial pneumonitis.
Collapse
Affiliation(s)
- M Ozsahin
- Department of Radiation Oncology, Hôpital Tenon, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Down JD, Berman AJ, Warhol M, Yeap B, Mauch P. Late complications following total-body irradiation and bone marrow rescue in mice: predominance of glomerular nephropathy and hemolytic anemia. Int J Radiat Biol 1990; 57:551-65. [PMID: 1968948 DOI: 10.1080/09553009014552691] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Late mortality and pathology were assessed in various mouse strains following total-body irradiation (TBI) and bone marrow transplantation. A, C57BL/6, B6AF1, LP and C3H mice received TBI in two fractions 3 h apart at total doses of between 11 and 15 Gy. They were then transplanted with syngeneic bone marrow cells providing sufficient reconstitution to avoid hemopoietic failure. Long-term survival data revealed both radiation dose- and strain-dependent onset of mortality between 1 and 2 years post-treatment. Renal damage appeared to have contributed to the late mortality in most treatment groups as shown by glomerular lesions, elevated blood urea nitrogen and an accompanying fall in hematocrit. Hemolysis was deduced to be the major cause of anemia, as concluded from results of 51Cr-labeled erythrocyte survival. No decrease in erythropoiesis was evident as seen from spleen and bone marrow 59Fe uptake. These findings are together consistent with the manifestation of a hemolytic uremic syndrome (HUS) with kidney glomeruli representing the principal sites of injury responsible for both renal dysfunction and microangiopathic hemolysis.
Collapse
Affiliation(s)
- J D Down
- Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115
| | | | | | | | | |
Collapse
|
5
|
Regnier R, Piron A, Debusscher L, van Houtte P. Total body irradiation: clinical experience at the Institute Jules Bordet. Radiother Oncol 1990; 18 Suppl 1:128-31. [PMID: 2247637 DOI: 10.1016/0167-8140(90)90192-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Our clinical experience with 58 patients receiving TBI as part of their treatment for a malignant hematopoietic disease suggests the following comments: 6 daily fractions of 2 Gy given over 6 days have a similar antitumoral effect as a single dose of 10 Gy, using a low dose rate, but with less toxicity. 7 daily fractions of 2.25 Gy given over 8 days exceed normal lung tolerance. No leukemia recurrence was observed among patients treated with 6 times 2 Gy but the maximal period of observation is only 560 days. On the other hand, a relapse was seen 2 years after 7 times 2.25 Gy. This may suggest the necessity to find a more effective drug regimen or to deliver additional radiation to possible sanctuary sites for chemotherapy.
Collapse
Affiliation(s)
- R Regnier
- Radiotherapy Department, Jules Bordet Institute, Brussels, Belgium
| | | | | | | |
Collapse
|
6
|
James ND, Apperley JF, Kam KC, MacKinnon S, Goldman JM, Goolden AW, Sikora K. Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia. Clin Radiol 1989; 40:195-8. [PMID: 2647359 DOI: 10.1016/s0009-9260(89)80094-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Between August 1985 and October 1987 we treated 35 patients with chronic myeloid leukaemia (CML) by high dose chemotherapy, total body irradiation (TBI) (1000 or 1200 cGy, n = 31) and total lymphoid irradiation (TLI) (800 or 600 cGy, n = 35) preceding allogeneic bone marrow transplantation (BMT). Both TBI and TLI were given at 200 cGy/fraction. Twenty-three patients had HLA-identical sibling donors, nine patients had HLA-matched but unrelated donors, and three partially HLA-mismatched donors. Twenty-two patients received T-cell depleted marrow. The addition of TLI to the standard protocol did not add greatly to the toxicity. Four patients had recurrent leukaemia before engraftment was evaluable. The other 31 patients engrafted and no graft failed. Twenty-two patients survive at a median time from transplant of 305 days (range 81-586 days). Fourteen have no evidence of disease; eight have or had only cytogenetic evidence of leukaemia. We conclude that the addition of TLI to pretransplant immunosuppression increases the probability of reliable engraftment in patients receiving T-cell depleted marrow. This benefit is not associated with significantly increased toxicity.
Collapse
MESH Headings
- Adolescent
- Adult
- Bone Marrow Transplantation
- Child
- Child, Preschool
- Combined Modality Therapy
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/radiotherapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Lymphatic Irradiation
- Middle Aged
- Whole-Body Irradiation
Collapse
Affiliation(s)
- N D James
- Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
| | | | | | | | | | | | | |
Collapse
|
7
|
Doughty D, Lambert GD, Hirst A, Marks AM, Plowman PN. Improved total-body irradiation dosimetry. Br J Radiol 1987; 60:269-78. [PMID: 3552096 DOI: 10.1259/0007-1285-60-711-269] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
The total-body irradiation (TBI) technique at St Bartholomew's Hospital has been developed to improve dose homogeneity within the patient. Using a standard 6 MV linear accelerator in an orthodox-sized treatment room, the midpoint doses in head, neck, shoulders, mid-mediastinum, pelvis, knees and ankles are +/- 5% of that of the umbilicus in our current technique. This homogeneity has been achieved by a four-field technique, a reproducible patient set-up, careful use of a new bolus material and an additional beam-flattening filter mounted near the machine head. In addition, thermoluminescent dosimetric data collected at a test irradiation before TBI are used to influence field weightings and further improve dosimetry. This individualised and empirical TBI technique has dosimetric advantages over theoretical TBI dosimetric considerations in reducing dose gradients within the patient. These advantages are discussed.
Collapse
|
8
|
O'Donoghue JA. Fractionated versus low dose-rate total body irradiation. Radiobiological considerations in the selection of regimes. Radiother Oncol 1986; 7:241-7. [PMID: 3544085 DOI: 10.1016/s0167-8140(86)80035-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Total body irradiation (TBI) followed by bone marrow rescue is being increasingly used in the systemic treatment of acute leukaemia and some solid tumours such as neuroblastoma. Typically, these neoplasms are radiosensitive with little or no shoulder on the in vitro survival curve (n approximately equal to 1.0, Do approximately equal to 1.0 Gy). In such cases, fractionated or low-dose-rate TBI should allow preferential sparing of normal tissues. With the appropriate choice of dose rate, low-dose-rate TBI should, in principle, be radiobiologically equivalent to fractionated TBI. Calculations based on an extension to the linear quadratic model suggest that extremely low dose rates (e.g., approximately equal to 0.5 Gy h-1) might be required for equivalence to conventionally fractionated schedules. Such low dose rates would require very long treatment times (e.g., approximately equal to 24 h), which renders them impractical. For cell survival parameters of typical radiosensitive neoplasms the effects of proliferation do not alter this conclusion. These studies suggest that fractionated TBI (with high dose rates) is preferable to low-dose-rate therapy for neoplasms such as leukaemia and neuroblastoma.
Collapse
|
9
|
Denham JW, Juttner CA, Ward GG, Kimber RJ, Ho JQ, Cross P, Smylie J, Schirmer M, Toogood I, Rice M. Total body irradiation and bone marrow transplantation in Adelaide--a short report on 7 years experience. AUSTRALASIAN RADIOLOGY 1986; 30:262-7. [PMID: 3545170 DOI: 10.1111/j.1440-1673.1986.tb01751.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
10
|
Abstract
The thorax of CBA mice was exposed to 60Co gamma-rays at dose rates ranging from 100 to 2 cGy/min. Iso-effect doses (ED50) were calculated for early and late lung damage from dose-response curves for breathing rate and lethality. A continuous increase in tolerance for early radiation pneumonitis was seen as the dose rate was reduced, reaching a dose recovery factor (DRF) of 2.6 at 2 cGy/min. There was significantly less dose sparing with 2 cGy/min for the rise in breathing rate during expression of late damage (DRF = 2.1). The lower DRF compared well with that obtained from late measurements of pleural fluid levels. Comparison with fractionation experiments indicated incomplete repair at 2 cGy/min with further dose recovery expected at even lower dose rates or at doses per fraction below 200 cGy. Since the dose-rate dependence of damage to haemopoietic tissue is less marked, this study predicts an advantage of employing low dose-rate total-body irradiation (TBI) in the treatment of bone-marrow transplant patients. A further gain in the therapeutic index may be expected using a hyperfractionated regime with small doses per fraction.
Collapse
|
11
|
Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314:202-7. [PMID: 3510388 DOI: 10.1056/nejm198601233140403] [Citation(s) in RCA: 290] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Between February 1981 and December 1984 we treated 52 patients with chronic myeloid leukemia in the chronic phase and 18 patients with more advanced disease by high-dose chemoradiotherapy followed by allogeneic bone marrow transplantation using marrow cells from HLA-identical sibling donors. In addition, the 40 patients who had not previously undergone splenectomy received radiotherapy to the spleen. To prevent graft versus host disease, cyclosporine was given either alone or in conjunction with donor marrow depleted of T cells. Of the 52 patients treated in the chronic phase, 38 are alive after a median follow-up of 25 months (range, 7 to 50); the actuarial survival at two years was 72 percent, and the actuarial risk of relapse was 7 percent. Of the 18 patients with more advanced disease, 4 have survived; the actuarial two-year survival was 18 percent, and the actuarial risk of relapse was 42 percent. We conclude that the probability of cure is highest if transplantation is performed while the patient remains in the chronic phase of chronic myeloid leukemia. T-cell depletion may have reduced the incidence and severity of graft versus host disease. The value of irradiation to the spleen before transplantation has not been established.
Collapse
|
12
|
Link H, Reinhard U, Walter E, Wernet P, Schneider EM, Fischbach H, Blaurock M, Wilms K, Niethammer D, Ostendorf P. Lung diseases after bone marrow transplantation. Results of a clinical, radiological, histological, immunological and lung function study. KLINISCHE WOCHENSCHRIFT 1986; 64:595-614. [PMID: 3528653 PMCID: PMC7095942 DOI: 10.1007/bf01735262] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The case histories of 72 subsequently treated patients - 44 with acute leukemia, 10 with chronic myeloid leukemia, 16 with severe aplastic anemia and 2 with neuroblastoma - were analyzed after bone marrow transplantation (BMT) with respect to pulmonary diseases. Thirty-eight patients suffered from a total of 51 pulmonary complications, which led to death in 20. Of 13 patients, 3 died of bacterial pneumonia, all of them during granulocytopenia; 2 of 6 patients died of fungal pneumonia and 2 out of 3 of a mixed bacterial-mycotic infection. Adult respiratory distress syndrome (ARDS) led to death in 2 patients. A granulocyte count under 500/microliter correlated significantly (P less than 0.002) with the fatal outcome of bacterial, fungal and ARDS pneumonia as well as with bronchitis. Viral pneumonia led to death in 8 of 9 patients; in each there was a significant correlation (P less than 0.05) with graft-versus-host disease (GvHD). Patients with repeated episodes of pulmonary illness had significantly more chronic GvHD (P less than 0.05); several of these patients displayed a reduction in helper T cells and an increase in suppressor T cells in the peripheral blood. The natural killer (NK) cells were reduced and the percentage of activated NK cell level lay between 6% and 69%. B-cells were absent or deficient. These findings explain in part the absence of specific antibody reactivity. Five of these patients also contracted GvHD-associated obstructive bronchiolitis, which did not respond to therapy. Pulmonary infiltrates of unknown origin (including idiopathic interstitial pneumonia) occurred in 8 of the patients (11.1%), with a fatal outcome in 3 patients. Significant changes (P less than 0.05) in lung function after BMT appeared in the form of reduced vital capacity (VC) increased residual volume (RV) and an increase in RV expressed as the percentage of total lung capacity. Pulmonary diseases were the most common complication and cause of death in our patients after BMT.
Collapse
|
13
|
Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58:515-28. [PMID: 4063711 DOI: 10.1259/0007-1285-58-690-515] [Citation(s) in RCA: 681] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
The linear-quadratic (LQ) dose-effect formalism is currently providing new perspectives into the ways in which alterations in the dose per fraction in conventional radiotherapy may be used to bring about improved results with respect to early or late normal tissue reactions. In this paper, using a model initially developed by Roesch, the LQ equations are explored further in terms of dose-rate rather than dose. By the incorporation of one other parameter, mu, which relates to the rate of repair of sub-lethal radiation damage, a more general formalism is obtained. In particular, equations are derived which can be used to examine the relative effectiveness of different treatment regimes, including those involving decaying sources. Such equations are of wider applicability than other LQ derivations which relate only to dose-response relationships. The extended equations, which are fully consistent with the existing LQ method, are also shown to lead directly to other independently established, relationships for protracted irradiation. The nature of the link between high and low dose-rate treatments is discussed, and some worked examples provide indications of how the new equations may be used to assess further the potential clinical benefits of low dose-rate treatments and permanent implants.
Collapse
|
14
|
Haines ME, Goldman JM, Worsley AM, McCarthy DM, Wyatt SE, Dowding C, Kearney L, Th'ng KH, Wareham NJ, Pollock A. Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. Br J Haematol 1984; 58:711-21. [PMID: 6151399 DOI: 10.1111/j.1365-2141.1984.tb06118.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Between June 1977 and July 1983 51 patients with Ph1-positive chronic granulocytic leukaemia (CGL) in transformation were treated either by chemotherapy or by chemoradiotherapy followed by autografting with haemopoietic stem cells collected from their peripheral blood at the time of diagnosis. Forty-eight patients were restored to a second chronic phase. The median duration of survival after autografting was 26 weeks (range 2-152 weeks). Twenty-one patients with relatively long durations of second chronic phase were treated again by autografting as consolidation or when transformation recurred; this selected group of patients survived longer than the 30 patients treated by autografting only once (medians 52 v. 13 weeks respectively, P less than 0.01). There was no significant influence of the patients' age, splenectomy status, type of transformation, treatment pre-autograft or number of nucleated cells autografted on the duration of survival. Three patients treated in myeloid blastic transformation were restored to partially Ph1-negative haemopoiesis. We conclude that this approach to the management of CGL in transformation can offer benefit for a minority of patients and that further chemotherapy and autografting for patients still in second chronic phase may be valuable.
Collapse
|
15
|
Baughan AS, Worsley AM, McCarthy DM, Hows JM, Catovsky D, Gordon-Smith EC, Galton DA, Goldman JM. Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: the influence of previous splenectomy. Br J Haematol 1984; 56:445-54. [PMID: 6365154 DOI: 10.1111/j.1365-2141.1984.tb03974.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Eighteen patients with chronic granulocytic leukaemia (CGL) were treated by chemoradiotherapy and transplantation of bone marrow (BMT) collected from their HLA-identical sibs; engraftment with donor marrow occurred in all cases. Ten of the patients had been subjected to splenectomy before BMT; recovery after BMT of granulocyte, lymphocyte and platelet numbers in the peripheral blood was more rapid in these patients than in the eight patients who retained their spleens. Acute graft-versus-host disease occurred in 12 of the 15 evaluable patients and appeared to be more severe in those who lacked their spleens at the time of transplant. Of the 12 patients surviving at follow-up times ranging from 59 to 207 weeks, six had been subjected to splenectomy before BMT and six retained their spleens. We conclude that engraftment was more rapid in the splenectomized patients and splenectomy might have increased the chance of eradicating the leukaemia, but these considerations must be balanced against the short-term and long-term risks associated with splenectomy.
Collapse
|